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may be the worst enemy of a timely
diagnosisTo face the challenge of the under-diagnosis of dementia
[1] and to meet the crucial need for its timely diagnosis [2],
many countries have adopted a stepwise case-finding diag-
nostic strategy [3,4]. The first step usually consists of
nonspecialist screening of cognitive impairment in a
primary care setting. If it is positive, the patient is referred
to a secondary care service where a full evaluation is
carried out; if it is negative, the patient is generally
referred to a follow-up screening some time later [4]. This
strategy probably represents a great advancement in the
diagnosis of dementia, and its efficacy is supported by
several lines of evidence indicating that cognitive screening
can considerably improve the identification of dementia [5].
Nonetheless, it should be noted that a nonspecialist first eval-
uation has the potential to be rather inaccurate. It can defi-
nitely result in false negatives as well as in false positives.
For instance, a recent study addressing the effect of
screening for cognitive impairment in elderly veterans has
shown that many individuals who were found to be normal
at a brief cognitive test were recognized as having dementia
at a subsequent full evaluation [6]. Conversely, a widespread
cognitive screening tool (i.e., the Montreal Cognitive
Assessment) was found to yield many false positives when
used to detect dementia [7]. A certain number of false neg-
atives may be acceptable for a case-finding strategy [4] and
false positives would be an economic, but not a diagnostic
issue, as overdiagnosis would likely be amended at the sec-
ond step of the full evaluation. However, to maximize the
benefits of a timely diagnosis of dementia, it is currently
believed that it should indeed be made at a prodromal (i.e.,
at mild cognitive impairment, MCI) stage [8]. At this stage,
wewould expect the first nonspecialist evaluation to be more
inaccurate, especially in terms of false negatives, as prodro-
mal signs of dementia can be subtle and difficult to recog-
nize and require more extensive cognitive examination [9].
Moreover, a missed detection could have worse conse-
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).than at a more advanced stage of dementia. In fact, it is likely
that patients with mild-to-moderate dementia unidentified at
the first screening would ask for a new referral very soon,
because of significant cognitive and/or behavioral distur-
bances causing distress to themselves and their families.
On the other hand, patients with prodromal dementia going
undetected on first screening might not feel the need for a
new referral for a long time, because their subtle or selective
disturbances are probably less distressing. Thus, an inaccu-
rate first detection of prodromal dementia can significantly
delay its recognition and become the worst enemy of a
timely diagnosis. In sum, the current diagnostic strategy
does not seem to be able to adequately cope with the chal-
lenge of a timely diagnosis of prodromal dementia and could
thus result in the loss of a whole range of potential benefits:
for patients (e.g., improving quality of life), caregivers (e.g.,
developing appropriate care plans), health care professionals
(e.g., providing patients and families with important infor-
mation), and society (e.g., reducing health care costs)
[3,8]. It is likely that in a near future, a more accurate
diagnosis of prodromal dementia will be possible in
primary care when reliable biomarkers of the disease (e.g.,
low Aß42 in the cerebrospinal fluid) or other attractive
advanced tests (e.g., the cholinergic stress test) [10] will
be routinely available in a clinical setting. In the meanwhile,
we believe that it is possible to improve the current strategy
by incorporating a new diagnostic stage between the nonspe-
cialist screening and the specialist full evaluation. We
envisage an intermediate stage—we may call it a “1.5 stage
of full detection”—where a “frontline” dementia specialist
(i.e., a behavioral neurologist, a neuropsychologist, a geria-
trician, an old age psychiatrist, or an advanced-practice
nurse) would cooperate side by side with the primary care
doctor, by performing additional skilled evaluations of the
patient’s cognitive, affective, and behavioral status. The im-
plementation of this new model in countries whose health
care system is organized in primary and secondary care
would require creating new shared spaces where a close
collaboration between generalists and specialists may be
achieved (e.g., district memory clinics) and converting a
number of specialists to full-time consultants for primary
care services. In conclusion, there is current emphasis on
the role of primary care services in the diagnosis and man-
agement of dementia, and this is certainly important, but it
should be borne in mind that we urgently need dementiaimer’s Association. This is an open access article under the CC BY-NC-ND
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ment of dementia at a prodromal stage. Yet, dementia
specialists are incredibly few [2], and it takes time to train
them. The clock is ticking.
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